ISPOR Article Notes Major Consequences if Reference Pricing is Implemented to Reduce Drug Costs
One solution for rising drug prices in the US is the use of reference pricing, rather than our current system [...]
Johns Hopkins Surgeon Discusses Soaring Healthcare Costs and Possible Solutions
In a recent podcast, Johns Hopkins surgical oncologist Marty Makary discusses how high costs affect patient care, the choice doctors [...]
Bipartisan Lawmakers Urge Action Over Hospital Pricing Noncompliance
In an effort to reduce healthcare costs, a new ruling mandates that hospitals be transparent about the prices they charge [...]
Bundled Payment Healthcare Program Saves Over $16,000 per Procedure and Leads to 75% Lower Readmission Rate
Carrum Health led a bundled payment program, resulting in substantial savings when it comes to the cost of surgical and [...]
Are They Really Orphans? New Report Highlights Misuse of Orphan Drug Designation Driving High Prices
A study recently published in Health Affairs examines whether or not orphan drugs fit the criteria allowing them special privileges [...]
PhRMA Kicks Off New Agenda, Including Endorsement of Drug Pricing Reforms
National lobbying group PhRMA introduced a new agenda this week with a pointed message at the White House: pharma has [...]
ICER Publishes Methodology on Evaluating Unsupported Drug Price Increases
ICER has released a protocol detailing how it analyses UPIs (Unsupported Price Increases) for prescription drugs in the United States. [...]
ICER Announces Final Evidence Report for FibroGen’s Roxadustat, Uncertainties Linger
ICER has released a final evidence report for roxadustat, along with policy recommendations. Cardiovascular risks were one of the concerns [...]
ICER To Review Hypertrophic Cardiomyopathy Drug
ICER has announced its intention to review mavacamten, a drug for use in hypertrophic cardiomyopathy. The Draft Scoping Document is [...]
Healthcare Spending in Massachusetts Increases, Drug Spending Largest Source of Growth
Massachusetts healthcare spending increased for the second year. Pharmacy services, hospital inpatient, hospital outpatient, and physician services all increased in [...]
ICER Releases Evidence Report on Lupus Nephritis Drugs
ICER has published a new evidence report on two drugs for use in lupus nephritis patients. FDA-approved voclosporin and belimumab [...]
New Article Details Medicaid Challenges for Individuals Approaching Poverty Definition, Note Over $2000 Excess Spending
According to a new report, people who exceed income requirements for Medicaid eligibility are affected by over $2000 in out-of-pocket [...]
Cost-Sharing Program Reduces Employer Healthcare Costs by 10%, Patient Costs by Nearly 30%
In a recent podcast, Christopher Whaley of the RAND Corporation discusses an article on reducing healthcare costs. The program takes [...]
Patients for Affordable Drugs Seeks Story Submissions
Patients for Affordable Drugs is seeking stories from patients facing high drug costs. Stories will be shared with lawmakers to [...]
New Report by Patient Coalition on Substandard Healthcare Plans Resulting in Patient Cost Burden
A coalition of 30 patient organizations advocating for healthcare access for patients with preexisting health conditions has released a new [...]
Two Online Decision Modelling Courses for Health Economists and Health Professionals
The London School of Hygiene & Tropical Medicine and the University of York have partnered to offer two online courses [...]
Understanding ICER’s New Life Years Metric
ICER (the Institute for Clinical and Economic Review) revealed a new metric in 2018: evLYG (equal value of life years [...]
Pharma Price Negotiations and Reimbursement Hurdles in Germany
Negotiating the prices of Advanced Therapy Medicinal Products (ATMPs) is a challenging and convoluted process in Germany. The majority of [...]
Why Does Pharma Make Record Profits From Taxpayer-Funded Research? Does Pricing Regulation Really Impact Innovation?
Vaccines have been developed quickly and efficiently since the start of the COVID-19 pandemic, in part due to taxpayer-supported funding. [...]
Comparing High US Drug Prices to Rest of World is Flawed, Reference Pricing Not a Solution
There are five key points driving high drug prices in the US, including better access in the US and robust [...]
ICER Announces New Governance Board Members in Push to Improve Drug Pricing and Health Equity
ICER (the Institute for Clinical and Economic Review) has announced the election of two members to its Governance Board: Joy [...]
Will States Look to ICER Reports in Legislative Measures to Regulate Drug Prices?
High drug prices are a national crisis. Policymakers in three different states (Washington, Maine, and Hawaii) have introduced price control [...]
How Do Bioisimilars Drive High Drug Prices? Proposed Drug Policy Could Save Americans $360 Billion
One proposed solution for high drug prices in the United States is the use of biosimilars. According to Peter Bach, [...]
Democratic and Republican Voters Agree on Lowering Extreme Drug Prices
A recent poll suggests that President Biden needs to take firm action on skyrocketing prescription drug prices. Prescription drug price [...]
Will Washington State Take on Drug Distribution Role?
A new bill would give the state of Washington’s Health Care Authority the power to distribute generic drugs and insulin [...]